These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28057014)

  • 1. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
    Feng KC; Guo YL; Liu Y; Dai HR; Wang Y; Lv HY; Huang JH; Yang QM; Han WD
    J Hematol Oncol; 2017 Jan; 10(1):4. PubMed ID: 28057014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
    Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
    Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
    Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
    Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
    Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma.
    Alnaggar M; Xu Y; Li J; He J; Chen J; Li M; Wu Q; Lin L; Liang Y; Wang X; Li J; Hu Y; Chen Y; Xu K; Wu Y; Yin Z
    J Immunother Cancer; 2019 Feb; 7(1):36. PubMed ID: 30736852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
    Sci Rep; 2021 Mar; 11(1):6276. PubMed ID: 33737613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
    Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
    Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement.
    Zhang Y; Zhang C; Zhou J; Zhang J; Chen X; Chen J; Wang P; Sun X; Lou X; Qi W; Kang L; Yu L; Wu D; Li C
    Front Immunol; 2021; 12():552429. PubMed ID: 33717057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
    Feng K; Guo Y; Dai H; Wang Y; Li X; Jia H; Han W
    Sci China Life Sci; 2016 May; 59(5):468-79. PubMed ID: 26968708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy.
    Abu-Sbeih H; Tang T; Ali FS; Luo W; Neelapu SS; Westin JR; Okhuysen PC; Foo WC; Curry JL; Richards DM; Ge PS; Wang Y
    Am J Clin Oncol; 2019 Oct; 42(10):789-796. PubMed ID: 31478934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
    Du J; Lv X; Zhang Z; Huang Z; Zhang E
    Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.
    Høgdall D; Lewinska M; Andersen JB
    Trends Cancer; 2018 Mar; 4(3):239-255. PubMed ID: 29506673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
    Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
    Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab].
    Kan N; Yoshikawa K; Matsushita N; Fujii T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1759-61. PubMed ID: 24393913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.
    Wang Y; Chen M; Wu Z; Tong C; Dai H; Guo Y; Liu Y; Huang J; Lv H; Luo C; Feng KC; Yang QM; Li XL; Han W
    Oncoimmunology; 2018; 7(7):e1440169. PubMed ID: 29900044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfated Galactans from Red Seaweed Gracilaria fisheri Target EGFR and Inhibit Cholangiocarcinoma Cell Proliferation.
    Sae-Lao T; Tohtong R; Bates DO; Wongprasert K
    Am J Chin Med; 2017; 45(3):615-633. PubMed ID: 28385079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future directions in the treatment of cholangiocarcinoma.
    Zhu AX
    Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):355-61. PubMed ID: 25966434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.